Amgen (NASDAQ:AMGN) SVP Nancy Grygiel Sells 2,970 Shares

Amgen Inc. (NASDAQ:AMGN) SVP Nancy Grygiel sold 2,970 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Amgen Stock Up 1.5%

NASDAQ:AMGN traded up $6.10 during midday trading on Friday, hitting $410.95. 1,821,460 shares of the company were exchanged, compared to its average volume of 2,750,778. The company has a fifty day simple moving average of $361.29 and a 200 day simple moving average of $355.86. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $418.40. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 4.44. The company has a market capitalization of $221.79 billion, a PE ratio of 25.54, a price-to-earnings-growth ratio of 4.10 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same period in the previous year, the company earned $6.02 earnings per share. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 22.47 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is presently 70.15%.

Institutional Trading of Amgen

Several institutional investors and hedge funds have recently added to or reduced their stakes in AMGN. Robeco Institutional Asset Management B.V. increased its holdings in shares of Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after acquiring an additional 43,884 shares during the period. Curtis Advisory Group LLC acquired a new position in Amgen during the 4th quarter valued at about $1,669,000. Adell Harriman & Carpenter Inc. boosted its stake in Amgen by 7.9% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after purchasing an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in Amgen in the 4th quarter worth about $22,441,000. Finally, Sigma Planning Corp grew its position in Amgen by 24.0% in the 4th quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock worth $5,889,000 after purchasing an additional 3,488 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on AMGN shares. Morgan Stanley lifted their price target on Amgen from $333.00 to $351.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Barclays increased their price objective on Amgen from $350.00 to $360.00 and gave the company an “equal weight” rating in a report on Wednesday, July 29th. Scotiabank lifted their target price on shares of Amgen from $385.00 to $450.00 and gave the company an “outperform” rating in a report on Wednesday. UBS Group upped their price target on shares of Amgen from $420.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Robert W. Baird increased their price target on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Amgen has an average rating of “Hold” and an average price target of $370.07.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.